FDA Approves ONSWIK KWIKPEN — Eli Lilly and Company
Eli Lilly and Company received FDA clearance on September 23, 2026, for ONSWIK KWIKPEN (insulin efsitora alfa-gobe), a bioengineered insulin offering novel pharmacokinetic properties via subcutaneous administration. The approval is poised to create a significant competitive headwind for the traditional insulin market, likely driving price pressure and reshaping the allocation of market share among major diabetic care providers.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed